Get the Stockscreener App
5.64
0.53%
-0.03
After Hours:
5.64
Foghorn Therapeutics Inc stock is traded at $5.64, with a volume of 146.28K.
It is down -0.53% in the last 24 hours and up +7.84% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.67
Open:
$5.63
24h Volume:
146.28K
Relative Volume:
0.90
Market Cap:
$330.40M
Revenue:
$24.52M
Net Income/Loss:
$-72.12M
P/E Ratio:
-4.7527
EPS:
-1.1867
Net Cash Flow:
$-88.88M
1W Performance:
-2.08%
1M Performance:
+7.84%
6M Performance:
-2.25%
1Y Performance:
+20.77%
1-Day Range:
$5.4275
$5.73
1-Week Range:
$5.32
$5.81
52-Week Range:
$2.9448
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.64 | 332.16M | 24.52M | -72.12M | -88.88M | -1.1867 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Resumed | Jefferies | Buy |
| Dec-18-25 | Initiated | BTIG Research | Buy |
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Foghorn Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Should you avoid Foghorn Therapeutics Inc. stock right nowJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday - Defense World
Foghorn Therapeutics (FHTX) grants CFO 400,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) CFO files Form 3 insider ownership - Stock Titan
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - Investing News Network
Foghorn Therapeutics names Ryan Maynard as chief financial officer By Investing.com - Investing.com India
Cancer-focused biotech Foghorn to present at two March investor forums - Stock Titan
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Foghorn Therapeutics names Ryan Maynard as chief financial officer - Investing.com
Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus
Foghorn Therapeutics Appoints Ryan Maynard CFO - marketscreener.com
Foghorn Therapeutics Names Veteran Executive as New CFO - TipRanks
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Ryan Maynard joins Foghorn Therapeutics (NASDAQ: FHTX) as new CFO - Stock Titan
Foghorn Therapeutics Inc. Announces Executive Changes - marketscreener.com
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Investment Review: Does Aris Mining Corporation have a competitive edgeQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Jefferies Financial Group Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Jefferies Lowers Price Target for Foghorn Therapeutics (FHTX) to $12.00 | FHTX Stock News - GuruFocus
Jefferies initiates Foghorn Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates Foghorn Therapeutics stock with buy rating - Investing.com
Can Foghorn Therapeutics Inc. stock double in the next yearProduct Launch & High Accuracy Investment Signals - mfd.ru
Foghorn Therapeutics appoints interim CFO Jeff Sacher - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - MarketBeat
Does Foghorn Therapeutics Inc. have strong fundamentalsWeekly Trade Report & Verified Short-Term Plans - mfd.ru
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.6%Should You Sell? - MarketBeat
Foghorn Therapeutics: Key Catalysts on the Horizon for Investors - AD HOC NEWS
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Investing News Network
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Foghorn Therapeutics Reports Q3 2025 Financial Results - MSN
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1%Time to Sell? - MarketBeat
Highs Report: Can Foghorn Therapeutics Inc maintain sales growth2025 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 - Investing.com Canada
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target - Investing.com Canada
Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Insider Trends: Will Foghorn Therapeutics Inc stock benefit from green energy trendsJuly 2025 Review & Real-Time Stock Movement Alerts - Bộ Nội Vụ
What momentum indicators show for Foghorn Therapeutics Inc. stockJuly 2025 Catalysts & Safe Entry Trade Signal Reports - ulpravda.ru
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):